

medium chain triglyceride oil, corn oil, soy lecithin, vitamins, minerals, fructooligosaccharides, lactose, gluten, and growth factor free) consumed by the mice was similar throughout the week (15 ml/day). Body weight did not differ between the Perative fed and chow fed groups. Northern blot analysis⁶ of total RNA extracted from the jejunum and ileum, using an oligo probe specific to cryptdin 1, cryptdin 2, and cryptdin 3 (>93% nucleotide identity), or cryptdin 4, revealed that levels of cryptdins 1–3 (fig 1A) and cryptdin 4 (fig 1B) increased by 1.6-fold (Student's *t* test, *p*<0.05).

To further study the direct effect of Perative on Paneth cells, we isolated primary Paneth cells⁷ from mouse jejunum and tested the effect of different concentrations of Perative (0.0025%, 0.01%, 0.025%), isoleucine, and arginine (25, 100, 250 µg/ml) on cryptdin expression by real time polymerase chain reaction.⁶ Whereas different concentrations of arginine and isoleucine did not stimulate cryptdin expression (Student's *t* test, *p*> 0.05), 0.025% Perative increased significantly expression of cryptdins 1–3 (Student's *t* test, *p*=0.003) (fig 1 C) and cryptdin 4 (Student's *t* test, *p*<0.0001) (fig 1C). The ability of similar concentrations of isoleucine and arginine to induce human β-defensin in HCT-116 cells⁸ stems, most probably, from the difference in the mechanism regulating expression of cryptdins (α-defensins) versus β-defensins. Different control of α- and β-defensin expression is further reiterated by the fact that spleens challenged with *Listeria monocytogenes*, lungs infected with influenza A, and kidneys challenged with *Candida albicans*, all β-defensin expressing tissues, revealed no differences in the cure rate when mice were fed Perative or other immune enhancing formulas.⁹

To further determine whether expression of cryptdin mRNA was concomitant with protein secretion in primary Paneth cells, we analysed the medium of primary Paneth cells stimulated with the aforementioned concentrations of isoleucine, arginine, and Perative. Cryptdins were isolated from the medium

using a method to denature, renature, and concentrate small cationic proteins¹⁰ followed by reverse phase high performance liquid chromatography.³ Protein data of the primary Paneth cell media correlated with that of RNA (that is, higher concentrations of secreted cryptdins were found in the 0.025% Perative treatment—data not shown). Furthermore, eluting fractions exhibited defensin characteristics, such as a size of 3 kDa on sodium dodecyl sulphate-polyacrylamide gel electrophoresis, and activity against *Escherichia coli* DH5α (data not shown).

In summary, our results demonstrate that immune enhancing formulas, such as Perative, can upregulate cryptdin expression in Paneth cells. Further study is needed to delineate the molecular pathways by which nutrients lead to cryptdin upregulation. As defensins display antimicrobial activity as well as recruit the adaptive immunity by cytokine secretion and recruitment of lymphocytes,^{2,3} their secretion could be the first step in a cascade that leads to a general bolstering of the immune system.

O Froy, G Levkovich, N Chapnik

Institute of Biochemistry, Food Science, and Nutrition, Faculty of Agriculture, Food, and Environmental Quality, The Hebrew University of Jerusalem, Rehovot, Israel

Correspondence to: Dr O Froy, Institute of Biochemistry, Food Science, and Nutrition, Faculty of Agriculture, Food, and Environmental Quality, The Hebrew University of Jerusalem. PO Box 12, Rehovot 76100, Israel; froy@agri.huji.ac.il

doi: 10.1136/gut.2006.092353

Conflict of interest: None declared.

References

- 1 **Bevins CL.** The Paneth cell and the innate immune response. *Curr Opin Gastroenterol* 2004;**20**:572–80.
- 2 **Yang D, Biragyn A, Kwak LW, et al.** Mammalian defensins in immunity: more than just microbicidal. *Trends Immunol* 2002;**23**:291–6.

- 3 **Lin PW, Simon PO, Gewirtz AT, et al.** Paneth cell cryptdins act in vitro as apical paracrine regulators of the innate inflammatory response. *J Biol Chem* 2004;**279**:19902–7.
- 4 **Bone RC, Balk RA, Cerra FB, et al.** Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest* 1992;**101**:1644–55.
- 5 **Beale RJ, Bryg DJ, Bihari DJ.** Immunonutrition in the critically ill: a systematic review of clinical outcome. *Crit Care Med* 1999;**27**:2799–805.
- 6 **Froy O, Chapnik N, Miskin R.** Mouse intestinal cryptdins exhibit circadian oscillation. *FASEB J* 2005;**19**:1920–2.
- 7 **Weiser MM.** Intestinal epithelial cell surface membrane glycoprotein synthesis. I. An indicator of cellular differentiation. *J Biol Chem* 1973;**248**:2536–41.
- 8 **Sherman H, Chapnik N, Froy O.** Albumin and amino acids upregulate the expression of human beta-defensin 1. *Mol Immunol* 2006 (in press) (Epub ahead of print, 29 Oct).
- 9 **Alder JD, Meulbroek J, Jarvis K, et al.** Enteral formula composition does not affect response to lethal infectious challenge in mice. *J Nutr* 1994;**124**:2156–62.
- 10 **Froy O, Zilberberg N, Gordon D, et al.** The putative bioactive surface of insect-selective scorpion excitatory neurotoxins. *J Biol Chem* 1999;**274**:5769–76.

A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations

Non-alcoholic fatty liver disease (NAFLD) may occur as an expression of a metabolic syndrome or in association with hepatitis C virus (HCV) chronic infection. The contemporaneous presence of NAFLD in this later group of patients may negatively affect the progression of fibrosis and the response to antiviral treatment.^{1,2} It has been suggested

Table 1 Results in the two groups; group A had primitive non-alcoholic fatty liver disease and group B had hepatitis C virus (HCV) related chronic hepatitis C in combination with NAFLD, all HCV genotype 1b, and were non-responders to previous antiviral treatment

	Treated			Not treated		
	Basal	6 months	12 months	Basal	6 months	12 months
Group A						
ALT (nv <40 U/l)	79 (51)	40 (15)**	59 (5)**	54.2 (20)	55.2 (24)	45.2 (34)
γGT (nv <50 U/l)	75 (112)	59 (100)**	60 (33)**	64 (20)	72 (24)	64 (35)
Insulinaemia (nv 5–25 µU/ml)	41.5 (34)	29.6 (26.4)*	30.6 (15.4)*	48.3 (17)	45.2 (12)	40.2 (11)
HOMA	12.3 (6.4)	6.2 (3.9)**	6.4 (3.2)**	13 (6)	11 (4)	11 (5)
Hyaluronic acid (nv <120 ng/ml)	383 (627)	176 (184)*	331.1 (293.2)	422 (504)	517 (283)	498 (145)
MMP-2 (nv 117–410 ng/ml)	151 (132)	141 (84)*	158.2 (165.5)	160 (183)	173 (102)	183 (97)
TGF-β (nv 34.7–63.9 ng/ml)	45.3 (17.3)	32.9 (24.3)*	42.9 (22)	41.2 (22)	43.3 (27.3)	44.7 (31)
US score (median (range))	2 (2–3)	1 (1–2)**	1 (1–2)**	2 (2–3)	2 (2–3)	2 (2–3)
Group B						
ALT (U/l)	69 (28)	45 (18)**	62 (16)	47.8 (30)	50.3 (32)	60.3 (33)
γGT (U/l)	118 (70)	56 (20)**	83 (24)	115 (60)	100 (53)	150 (13)
Insulinaemia (µU/ml)	36.2 (1.5)	27.4 (1.5)*	28.9 (6.5)*	35.4 (3)	34.2 (5.7)	38.2 (4.7)
HOMA	8.4 (7.3)	6 (4.8)*	6.2 (5.1)*	9.8 (5.6)	8.4 (5.1)	8.2 (4.8)
Hyaluronic acid (ng/ml)	1295 (259)	625 (122)*	586.7 (496.2)*	1180 (703)	1372 (806)	1332 (452)
MMP-2 (ng/ml)	292 (201)	137 (53)*	196.6 (94.2)*	280 (300)	311 (278)	299 (123)
TGF-β (ng/ml)	54.1 (21.7)	27 (12.2)*	21.2 (17.4)*	53.3 (18.3)	45.2 (28.5)	49.6 (30)
US score (median (range))	2 (2–3)	2 (2–3)	2 (2–3)	2 (2–3)	2 (2–3)	2 (2–3)

p*<0.05, *p*<0.01 versus basal values.

Values are reported as the mean (SD).

ALT, alanine aminotransferase; γGT, gamma-glutamyl-transpeptidase; MMP-2, metalloproteinase 2; TGF-β, transforming growth factor β; US, ultrasonography; nv, normal value.

that in the future a therapeutic approach to chronic liver disease would consist of a number of complementary approaches considering the multitude of pathogenic mechanisms.³ Silybin is a natural flavonoid that has been conjugated to vitamin E and phospholipids to improve its bioavailability, and antioxidant and antifibrotic activity.⁴

After approval of the ethics committee and informed consent, 85 outpatients were consecutively enrolled in the study: 59 were affected by primitive NAFLD (group A) and 26 by HCV related chronic hepatitis C in combination with NAFLD, all HCV genotype 1b, and non-responders to previous antiviral treatment (group B). All patients with a diagnosis of liver disease in the two years prior to the study, according to histological criteria,^{5,6} were enrolled over six consecutive months and further divided into two subgroups using a systematic random sampling procedure: 53 (39 NAFLD and 14 HCV) were treated with 4 pieces/day of the complex silybin-vitamin E-phospholipids (Realsil (RA); IBI-Lorenzini Pharmaceutical, Italy) for six months followed by another six months of follow up, while the other 32 patients (20 NAFLD and 12 HCV) served as a control group (no treatment). One piece contained 94 mg of silybin, 194 mg of phosphatidylcholine, and 90 mg of vitamin E.

At 0, 6, and 12 months, we evaluated: body mass index (BMI), bright liver by ultrasonography (US), aspartate aminotransferase, alanine aminotransferase, and gamma glutamyl-transpeptidase (γ GT) levels, blood glucose and insulin plasma levels with a contemporaneous determination of insulin resistance by HOMA test⁷ and, as indices of liver fibrosis, plasma levels of transforming growth factor β , hyaluronic acid, and metalloproteinase 2, by commercial ELISA kits.⁸ Results were analysed by ANOVA, the Wilcoxon and χ^2 tests to evaluate differences among groups and percentages of frequency, and by the Pearson bivariate correlation test to evaluate correlations among data.

There were no adverse events during the treatment and study compliance was absolute. All patients were asked to follow a well balanced individual diet during the study. BMI increased in approximately 70% of cases under basal conditions and did not vary significantly between groups, with the exception of HCV treated patients. In fact, only in this group, at six and 12 months, did the percentage of overweight patients decrease significantly (44%; $p < 0.01$ v basal and other group data). US steatosis, graded from 0 to 3,⁹ was significantly improved in the NAFLD treated group ($p < 0.01$ v others). Table 1 summarises the other results.

Liver enzyme levels showed an improvement in treated individuals but this only persisted in group A. Hyperinsulinaemia, present in both groups, was significantly reduced only in treated patients. Treatment with RA significantly reduced all indices of liver fibrosis in both treated groups, with a persistent effect only in group B.

A significant correlation among indices of fibrosis, BMI, insulinaemia, degree of US steatosis, and γ GT was found ($p < 0.01$). Despite two main drawbacks in this study (absence of a placebo treatment and no histological examination at the end of the study), the data suggest that this new complex of silybin-vitamin E-phospholipids should be tested in a well controlled larger trial to further confirm its possible therapeutic effect on insulin resistance and liver

damage, particularly when other drugs are not indicated or have failed, or as a complementary treatment associated with other therapeutic programmes.

A Federico, M Trappoliere, C Tuccillo, I de Sio, A Di Leva, C Del Vecchio Blanco, C Loguercio
Interuniversity Research Centre on Foods, Nutrition and Gastrointestinal Tract (CIRANAD), Unit of Gastroenterology, 2nd University of Naples, Naples, Italy

Correspondence to: Professor C Loguercio, Interuniversity Research Centre on Foods, Nutrition and Gastrointestinal Tract (CIRANAD), Unit of Gastroenterology, 2nd University of Naples, Via Foria 58-80131 Naples, Italy; carmelina.loguercio@unina2.it

doi: 10.1136/gut.2006.091967

Conflict of interest: None declared.

References

- 1 Patrick L. Hepatitis C. Epidemiology and review of complementary/alternative medicine treatments. *Altern Med Rev* 1999;4:220-38.
- 2 Younossi ZM, McCullough AJ, Ong JP, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. *J Clin Gastroenterol* 2004;38:705-9.
- 3 Bean P. The use of alternative medicine in the treatment of hepatitis C. *Am Clin Lab* 2002;21:19-21.
- 4 Zhao J, Agarwal R. Tissue distribution of silybinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. *Carcinogenesis* 1999;20:2101-8.
- 5 Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. *Semin Liver Dis* 2001;21:3-16.
- 6 Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. *J Hepatol* 1995;22:696-9.
- 7 Melchionda N, Forlani G, Marchesini G, et al. WHO and ADA criteria for the diagnosis of diabetes mellitus in relation to body mass index. Insulin sensitivity and secretion in resulting subcategories of glucose tolerance. *Int J Obes Relat Metab Disord* 2002;26:90-6.
- 8 Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. *Gastroenterology* 2004;127:1704-13.
- 9 Joseph AE, Soverymuttu SH, al-Sam S, et al. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. *Clin Radiol* 1991;9:91-4.

Is the periodic repetition of a coagulation check necessary during anti-hepatitis C virus therapy?

Peginterferon α and ribavirin have become the mainstay of treatment for chronic hepatitis C virus (HCV) infection.¹ However, chronic use of interferon (IFN)- α has been associated with the development of autoimmune disorders, such as systemic lupus erythematosus, autoimmune haemolytic anaemia, and autoimmune thyroiditis. In particular, some reports have documented the development of acquired factor VIII inhibitors in patients receiving IFN- α , including those treated for chronic HCV infection.²⁻⁶

We report the case of a 49 year old male patient treated for chronic active HCV related cirrhosis. He received a six month course of peginterferon α 2a at a dose of 180 μ g weekly and ribavirin at a dose of 800 mg daily for three months only, due to a marked decrease

in haemoglobin level, obtaining a complete viral response. Before therapy, activated partial thromboplastin time (aPTT) and prothrombin time-international normalised ratio (PT-INR) values were in the normal range (aPTT ratio 1.28 and INR 1.11). Due to abnormal bleeding during a routine dental treatment performed at the end of antiviral treatment in September 2005, the patient underwent a coagulation screening which revealed a prolonged aPTT (2.14; normal range 0.85-1.17). Coagulant factor VIII level was reduced (FVIII:C 17%; normal range 50-150%) and a mixing study demonstrated the presence of a low titre inhibitor (1.6 Bethesda units/ml). Response to subcutaneous injection of desmopressin at a dose of 0.3 mg/kg was satisfactory as FVIII:C increased to 70% and aPTT normalised four hours after injection. Recent tests performed three months after the end of antiviral treatment (November 2005) were unchanged.

If our case report provides further evidence in favour of the association between chronic exposure to peginterferon and the development of acquired factor VIII inhibitors, it raises several important questions too. Firstly, what is the real incidence of this phenomenon in patients treated for HCV infection? Are these inhibitors so rare as initially believed or are they misdiagnosed? Are they clinically relevant, what is the natural history of the coagulative alteration (that is, do they require treatment or do they tend to disappear spontaneously), and which is the best treatment? In our opinion, a response to these concerns may be obtained only through a careful coagulation study (especially aPTT ratio) of these patients during and after IFN treatment.

F Capra, N Nicolini

Medicina Interna A, Dipartimento di Scienze Biomediche e Chirurgiche, Università di Verona, Verona, Italy

M Franchini

Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy

Correspondence to: Dr M Franchini, Servizio di Immunoematologia e Trasfusione, Ospedale Policlinico, Piazzale L Scuro, 10, 37134 Verona, Italy; mfranchini@univr.it

doi: 10.1136/gut.2006.091496

Conflict of interest: None declared.

References

- 1 Lauer GM, Walker BD. Hepatitis C virus infection. *N Engl J Med* 2001;345:41-52.
- 2 Stricker RB, Barlogie B, Kiprov DD. Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy. *J Rheumatol* 1994;21:350-2.
- 3 Sallah S, Wan YJ. Inhibitors against factor VIII associated with the use of interferon-alpha and fludarabine. *Thromb Haemost* 2001;86:1119-21.
- 4 Castenskiöld EC, Colvin BT, Kelsey SM. Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy in a patient with haemophilia A. *Br J Haematol* 1994;87:434-6.
- 5 Herman C, Boggio L, Green D. Factor VIII inhibitor associated with peginterferon. *Haemophilia* 2005;11:408-10.
- 6 Schreiber ZA, Brau N. Acquired factor VIII inhibitor in patients with hepatitis C virus infection and the role of interferon-alpha: A case report. *Am J Hematol* 2005;80:295-8.
- 7 Franchini M, Gandini G, Di Paolantonio T, et al. Acquired hemophilia A: a concise review. *Am J Hematol* 2005;80:55-63.